Isomorphic Labs Secures $2.1B for AI Drug Development
Isomorphic Labs closed a $2.1 billion Series B funding round to scale its AI drug design platform and move candidate drugs toward clinical trials. Thrive Capital led the round, with backing from existing investors Alphabet and GV plus new backers CapitalG, MGX, Temasek, and the UK Sovereign AI Fund.
The company will use the capital to expand its IsoDDE drug design engine and accelerate its pipeline of therapeutic programs. The funding also supports hiring across AI, clinical, drug design, and engineering roles across all sites.
What IsoDDE Does
IsoDDE is Isomorphic Labs' unified AI platform built from multiple models that work across different therapeutic areas and drug modalities. Recent publications show the system's performance in structure prediction and real-world drug discovery applications.
Max Jaderberg, Isomorphic Labs president, said the engine has already hit key milestones in internal programs and identified viable candidates at speeds the company describes as unprecedented. "Our drug design engine works, and it's giving us a repeatable way to design new medicines for a wide range of diseases," Jaderberg said.
Industry Validation
Novartis, Johnson & Johnson, and Eli Lilly have signed strategic collaborations with Isomorphic Labs, signaling industry confidence in the AI-driven approach.
This Series B round follows a $600 million Series A in March 2025, the company's first external funding for AI-driven drug discovery.
Your membership also unlocks:
